Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O94925
UPID:
GLSK_HUMAN
Alternative names:
K-glutaminase; L-glutamine amidohydrolase
Alternative UPACC:
O94925; Q9UL05; Q9UL06; Q9UL07; Q9UN40
Background:
Glutaminase kidney isoform, mitochondrial, also known as K-glutaminase and L-glutamine amidohydrolase, plays a pivotal role in renal catabolism of glutamine and in maintaining acid-base homeostasis. It regulates neurotransmitter glutamate levels, crucial for brain function.
Therapeutic significance:
Linked to diseases like Developmental and epileptic encephalopathy 71, and others involving glutamate excess and neurodevelopmental issues, understanding Glutaminase kidney isoform's role could lead to novel therapeutic strategies.